Robert Lechleider Sells 55,000 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider sold 55,000 shares of Immunome stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $22.62, for a total transaction of $1,244,100.00. Following the sale, the insider owned 15,805 shares of the company’s stock, valued at approximately $357,509.10. This represents a 77.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Lechleider also recently made the following trade(s):

• On Thursday, June 25th, Robert Lechleider sold 55,000 shares of Immunome stock. The stock was sold at an average price of $19.85, for a total transaction of $1,091,750.00.

Immunome Price Performance

Shares of NASDAQ:IMNM traded up $0.49 during mid-day trading on Tuesday, reaching $24.39. 1,561,508 shares of the company were exchanged, compared to its average volume of 1,438,372. The firm has a market cap of $2.76 billion, a price-to-earnings ratio of -10.25 and a beta of 2.07. The firm’s 50-day simple moving average is $20.97 and its 200 day simple moving average is $21.79. Immunome, Inc. has a 1 year low of $7.96 and a 1 year high of $27.65.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. On average, research analysts forecast that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Pivotal bioVenture Partners Investment Advisor LLC purchased a new stake in shares of Immunome during the third quarter worth approximately $5,884,000. Nan Fung Trinity HK Ltd. grew its holdings in Immunome by 20.7% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company’s stock worth $15,349,000 after acquiring an additional 122,450 shares in the last quarter. SG Americas Securities LLC grew its holdings in Immunome by 1,749.3% during the 4th quarter. SG Americas Securities LLC now owns 162,168 shares of the company’s stock worth $3,483,000 after acquiring an additional 153,399 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Immunome by 23.4% in the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after purchasing an additional 1,144,788 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Immunome in the 4th quarter valued at approximately $3,652,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently commented on IMNM shares. Wedbush restated an “outperform” rating and set a $31.00 target price on shares of Immunome in a report on Friday, June 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Leerink Partners lowered their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Immunome in a report on Wednesday, May 13th. Finally, Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.